Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ecopetrol SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.66 (market cap $29.60B), while Ecopetrol SA trades at $17.01 (market cap $33.69B). The key difference: Alnylam Pharmaceuticals, Inc. and Ecopetrol SA are close in size by market cap, and Ecopetrol SA pays a 3.82% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EC | |
|---|---|---|
Market Cap | $29.60B | $33.69B |
Sector | Health | Energy |
52-Week High | $491.22 | $17.40 |
52-Week Low | $205.48 | $8.56 |
Enterprise Value | $27.56B | $63.86B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Ecopetrol (EC) trades at $17.05, up 1.61% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but showing declining revenue trends from $119.69T in 2025 to $116.95T projected for 2026. Recent developments include a cybersecurity incident in July 2026 and ongoing acquisition activities in Brazil's energy sector through Brava Energia.
The stock presents a value opportunity with attractive valuation ratios (P/E 11.11, P/S 0.97) but faces headwinds from declining revenue and profit margins. Analyst consensus is cautious with a $15 price target below current levels, while institutional sentiment shows mixed ratings amid operational challenges and cybersecurity risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
